Novel therapies for hereditary angioedema.
Advances in our understanding of the molecular mechanisms underlying hereditary angioedema (HAE) have led to the development of new treatment modalities. Five new drugs for the treatment of HAE are currently undergoing clinical testing in the United States. These novel therapeutics can be divided into two groups: drugs that replace C1 inhibitor (C1INH) functional activity and drugs that abrogate the bradykinin-mediated increase in vascular permeability associated with HAE attacks. The first group includes two plasma-derived C1INH concentrates as well as a recombinant transgenic human C1INH protein, and the second group includes an engineered plasma kallikrein inhibitor as well as a B2 bradykinin receptor antagonist. This article reviews the rationale, development, and potential use of these novel therapeutics.
Zuraw
Bruce L
BL
University of California San Diego, La Jolla, CA 92093-0732, USA. bzuraw@ucsd.edu
D000799:Angioedema / Q000188:drug therapy*; D000818:Animals; D001920:Bradykinin / Q000037:antagonists & inhibitors / Q000187:drug effects; D002986:Clinical Trials as Topic; D050718:Complement C1 Inhibitor Protein / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use
D050718:Complement C1 Inhibitor Protein; D011994:Recombinant Proteins; D007610:Kallikreins; D001920:Bradykinin